CV Therapeutics, headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development, and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product is Ranexa^® (ranolazine extended-release tablets). Ranexa is the first new pharmaceutical approach to treat chronic angina in the United States in more than 20 years. Complete safety and prescribing information can be found at www.Ranexa.com.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Regadenoson has not been approved for marketing by any regulatory authorities.

Corporate Presentations

 Download the CV Therapeutics Corporate Presentation

 Download the 2008 Investor Science Day Presentation

Access the 2008 Investor Science Day Webcast Archive



Recent News

View all press releases >>

6/24/2008	Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
6/23/2008	CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
5/28/2008	CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350